Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 8 de 8
Filtrer
Plus de filtres











Base de données
Gamme d'année
3.
Mech Ageing Dev ; 205: 111686, 2022 07.
Article de Anglais | MEDLINE | ID: mdl-35609733

RÉSUMÉ

Recent evidence demonstrates that Crocus sativus L. (saffron) counteracts oxidative stress, mitochondrial dysfunction and neuroinflammation, closely linked to initiation and progression of major brain pathologies. Interestingly, saffron constituents such as crocin, crocetin and safranal can exert antioxidant or toxic effects depending on their endogenous concentration. According to the hormesis principles, at low dose they act as antioxidants in a wide range of brain diseases by upregulating Nrf2 signaling pathway and the expression of vitagenes, such as NAD(P)H-quinone oxidoreductase (NQO1), glutathione transferase (GT), heme oxygenase-1 (HO-1), sirtuin-1 (Sirt1) and thioredoxin (Trx) system. Importantly, neuronal dysregulation of Nrf2 pathway can be a prominent cause of selective susceptibility, under neuroinflammatory conditions, due to the high vulnerability of brain cells to oxidative stress. Here we discuss natural inducers from saffron targeting Nrf2/vitagene pathway for development of new therapeutical strategies to suppress oxidative stress and neuroinflammation and consequently cognitive dysfunction. In this review we also focus on the hormetic effect of saffron active constituents, summarizing their neuroprotective and anti-neuroinflammatory properties, as well as pharmacological perspectives in brain disorders.


Sujet(s)
Encéphalopathies , Crocus , Antioxydants/pharmacologie , Antioxydants/usage thérapeutique , Humains , Facteur-2 apparenté à NF-E2 , Oxydoréduction , Extraits de plantes/pharmacologie , Extraits de plantes/usage thérapeutique
4.
Mol Neurobiol ; 54(8): 5973-5987, 2017 10.
Article de Anglais | MEDLINE | ID: mdl-27686077

RÉSUMÉ

Melatonin is the principal secretory product of the pineal gland, and its role as an immunomodulator is well established. Recent evidence shows that melatonin is a scavenger of oxyradicals and peroxynitrite and reduces the development of inflammation and tissue injury events associated with spinal cord trauma. Previous results suggest that peroxisome proliferator-activated receptor α (PPAR-α), a nuclear receptor protein that functions as a transcription factor activated by fatty acids, plays a role in control of secondary inflammatory process associated with spinal cord injury (SCI).With the aim to characterize the role of PPAR-α in melatonin-mediated anti-inflammatory activity, we tested the efficacy of melatonin (30 mg/kg) in an experimental model of spinal cord trauma, induced in mice, by the application of vascular clips (force of 24 g) to the dura via a four-level T5-T8 laminectomy, and comparing mice lacking PPAR-α (PPAR-α KO) with wild-type (WT) mice.The results obtained indicate that melatonin-mediated anti-inflammatory activity is weakened in PPAR-α KO mice, as compared to WT controls. In particular, melatonin was less effective in PPAR-α KO, compared to WT mice, as evaluated by inhibition of the degree of spinal cord inflammation and tissue injury, neutrophil infiltration, pro-inflammatory cytokine expression, nuclear factor κB (NF-κB) activation, and inducible nitric oxide synthase (iNOS) expression. This study indicates that PPAR-α can contribute to the anti-inflammatory activity of melatonin in SCI.


Sujet(s)
Anti-inflammatoires/pharmacologie , Inflammation/traitement médicamenteux , Mélatonine/pharmacologie , Récepteur PPAR alpha/métabolisme , Traumatismes de la moelle épinière/métabolisme , Animaux , Apoptose/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Souris knockout , Facteur de transcription NF-kappa B/métabolisme , Infiltration par les neutrophiles/effets des médicaments et des substances chimiques , Nitric oxide synthase type II/métabolisme , Récepteur PPAR alpha/génétique , Traumatismes de la moelle épinière/traitement médicamenteux , Facteur de nécrose tumorale alpha/métabolisme
5.
Immun Ageing ; 13: 23, 2016.
Article de Anglais | MEDLINE | ID: mdl-27398086

RÉSUMÉ

BACKGROUND: There has been a recent upsurge of interest in complementary medicine, especially dietary supplements and foods functional in delaying the onset of age-associated neurodegenerative diseases. Mushrooms have long been used in traditional medicine for thousands of years, being now increasingly recognized as antitumor, antioxidant, antiviral, antibacterial and hepatoprotective agent also capable to stimulate host immune responses. RESULTS: Here we provide evidence of neuroprotective action of Hericium Herinaceus when administered orally to rat. Expression of Lipoxin A4 (LXA4) was measured in different brain regions after oral administration of a biomass Hericium preparation, given for 3 month. LXA4 up-regulation was associated with an increased content of redox sensitive proteins involved in cellular stress response, such as Hsp72, Heme oxygenase -1 and Thioredoxin. In the brain of rats receiving Hericium, maximum induction of LXA4 was observed in cortex, and hippocampus followed by substantia Nigra, striatum and cerebellum. Increasing evidence supports the notion that oxidative stress-driven neuroinflammation is a fundamental cause in neurodegenerative diseases. As prominent intracellular redox system involved in neuroprotection, the vitagene system is emerging as a neurohormetic potential target for novel cytoprotective interventions. Vitagenes encode for cytoprotective heat shock proteins 70, heme oxygenase-1, thioredoxin and Lipoxin A4. Emerging interest is now focussing on molecules capable of activating the vitagene system as novel therapeutic target to minimize deleterious consequences associated with free radical-induced cell damage, such as in neurodegeneration. LXA4 is an emerging endogenous eicosanoid able to promote resolution of inflammation, acting as an endogenous "braking signal" in the inflammatory process. In addition, Hsp system is emerging as key pathway for modulation to prevent neuronal dysfunction, caused by protein misfolding. CONCLUSIONS: Conceivably, activation of LXA4 signaling and modulation of stress responsive vitagene proteins could serve as a potential therapeutic target for AD-related inflammation and neurodegenerative damage.

6.
Eur J Pharmacol ; 782: 107-18, 2016 07 05.
Article de Anglais | MEDLINE | ID: mdl-27095683

RÉSUMÉ

Palmitoylethanolamide (PEA), a special food for medical purposes, has anti-inflammatory and neuroprotective effects. Nevertheless, PEA lacks direct ability to prevent free radical formation. Polydatin (PLD), a natural precursor of resveratrol, has antioxidant activity. The combination of PEA and PLD could have beneficial effects on oxidative stress induced by inflammatory processes. In the present study, we compared the effects of micronized PEA (PEA-m) and PLD association (PEA-m+PLD) with a new co-micronized composite containing PEA and PLD (m(PEA/PLD)) in the rat paw model of carrageenan (CAR)-induced acute inflammation. Intraplantar injection of CAR led to a time-dependent development of peripheral inflammation, in terms of paw edema, cytokine release in paw exudates, nitrotyrosine formation, inducible nitric oxide synthase and cyclooxygenase-2 expression. m(PEA/PLD) reduced all measured parameters. Thermal hyperalgesia and mechanical allodynia were also markedly reduced. At the spinal cord level, manganese superoxide dismutase (MnSOD) was found to be nitrated and subsequently deactivated. Further, m(PEA/PLD) treatment increased spinal MnSOD expression, prevented IkB-α degradation and nuclear factor-κB translocation, suggesting a possible role on central sensitization. m(PEA/PLD) showed more robust anti-inflammatory and anti-hyperalgesic effects compared to the simple association of PEA-m and PLD. This composite formulation approach opens a new therapeutic strategy for the development of novel non-narcotic anti-hyperalgesic agents.


Sujet(s)
Carragénane/pharmacologie , Oedème/induit chimiquement , Oedème/traitement médicamenteux , Éthanolamines/composition chimique , Éthanolamines/pharmacologie , Glucosides/composition chimique , Glucosides/pharmacologie , Acides palmitiques/composition chimique , Acides palmitiques/pharmacologie , Stilbènes/composition chimique , Stilbènes/pharmacologie , Transport nucléaire actif/effets des médicaments et des substances chimiques , Administration par voie orale , Amides , Animaux , Lignée cellulaire tumorale , Noyau de la cellule/effets des médicaments et des substances chimiques , Noyau de la cellule/métabolisme , Cyclooxygenase 2/métabolisme , Cytokines/métabolisme , Modèles animaux de maladie humaine , Préparation de médicament , Interactions médicamenteuses , Oedème/immunologie , Oedème/métabolisme , Éthanolamines/administration et posologie , Éthanolamines/usage thérapeutique , Régulation de l'expression des gènes codant pour des enzymes/effets des médicaments et des substances chimiques , Glucosides/administration et posologie , Glucosides/usage thérapeutique , Hyperalgésie/traitement médicamenteux , Inflammation/induit chimiquement , Inflammation/traitement médicamenteux , Inflammation/immunologie , Inflammation/métabolisme , Mâle , Inhibiteur alpha de NF-KappaB/métabolisme , Infiltration par les neutrophiles/effets des médicaments et des substances chimiques , Nitric oxide synthase type II/métabolisme , Acides palmitiques/administration et posologie , Acides palmitiques/usage thérapeutique , Protéolyse/effets des médicaments et des substances chimiques , Rats , Rat Sprague-Dawley , Stilbènes/administration et posologie , Stilbènes/usage thérapeutique , Superoxide dismutase/métabolisme , Facteur de transcription RelA/métabolisme , Tyrosine/analogues et dérivés , Tyrosine/biosynthèse
7.
Neurotoxicology ; 53: 350-358, 2016 Mar.
Article de Anglais | MEDLINE | ID: mdl-26433056

RÉSUMÉ

Increasing evidence supports the notion that oxidative stress-driven neuroinflammation is an early pathological feature in neurodegenerative diseases. As a prominent intracellular redox system involved in neuroprotection, the vitagene system is emerging as a potential neurohormetic target for novel cytoprotective interventions. Vitagenes encode for cytoprotective heat shock proteins 70, heme oxygenase-1, thioredoxin and lipoxin A4. Emerging interest is now focusing on molecules capable of activating the vitagene system as novel therapeutic targets to minimize deleterious consequences associated with free radical-induced cell damage, such as in neurodegeneration. Mushroom-derived lipoxin A4 (LXA4) is an emerging endogenous eicosanoid able to promote resolution of inflammation, acting as an endogenous "braking signal" in the inflammatory process. Mushrooms have long been used in traditional medicine for thousands of years, being now increasingly recognized as rich source of polysaccharopeptides endowed with significant antitumor, antioxidant, antiviral, antibacterial and cytoprotective effects, thereby capable of stimulating host immune responses. Here we provide evidence of a neuroprotective action of the Coriolus mushroom when administered orally to rat. Expression of LXA4 was measured in different brain regions after oral administration of a Coriolus biomass preparation, given for 30 days. LXA4 up-regulation was associated with an increased content of redox sensitive proteins involved in cellular stress response, such as Hsp72, heme oxygenase-1 and thioredoxin. In the brain of rats receiving Coriolus, maximum induction of LXA4 was observed in cortex and hippocampus. Hsps induction was associated with no significant changes in IkBα, NFkB and COX-2 brain levels. Conceivably, activation of LXA4 signaling and modulation of stress-responsive vitagene proteins could serve as a potential therapeutic target for AD-related inflammation and neurodegenerative damage.


Sujet(s)
Encéphale/métabolisme , Coprinus/métabolisme , Lipoxines/métabolisme , Stress oxydatif/physiologie , Animaux , Coprinus/composition chimique , Cyclooxygenase 2/métabolisme , Heme oxygenase-1 , Protéines I-kappa B/métabolisme , Rein/métabolisme , Foie/métabolisme , Lymphocytes/effets des médicaments et des substances chimiques , Mâle , Nitric oxide synthase type II , Oxydoréduction , Rats , Rat Sprague-Dawley , Thiorédoxines , Facteur de transcription RelA/métabolisme , Régulation positive
8.
Toxicol Lett ; 240(1): 10-21, 2016 Jan 05.
Article de Anglais | MEDLINE | ID: mdl-26474837

RÉSUMÉ

Contrast-induced nephropathy (CIN) is a complication in patients after administration of iodinated contrast media. Several risk factors contribute to the development and progression of CIN, including hypertension, diabetes, and dyslipidemia. Animal models of CIN by surgical intervention to reproduce its clinical and pathology has been developed, and thus, therapeutic methods tested. Palmitoylethanolamide (PEA) is a member of the fatty acid ethanolamine family with analgesic and anti-inflammatory effects. In this study, we analyzed streptozotocin-induced diabetes model and in an another set of experiment a surgical remotion of the kidney with the aim of evaluating effect of ultramicronized Palmitoylethanolamide (PEA-um(®)) on contrast induced renal disfunction and glomerular morphology alteration. In a first step of our study, we demonstrated that PEA-um(®) significantly reduced CIN-mediated glomerular dysfunction, modulates Na(+) and K(+) levels in plasma and decreased urine and plasma NGAL levels and α-GST urine levels. Moreover, in a second set of experiment we investigated how PEA-um(®) reduced creatinine and BUN plasma levels after nephrectomy, ameliorate renal and medullary blood flow and re-established renal parenchymal after CIN induction as well as after nephrectomy. Take together our results demonstrated that PEA-um(®) are able to preventing CIN in diabetic rats and alteration of biochemical parameters after nephrectomy.


Sujet(s)
Analgésiques/pharmacologie , Anti-inflammatoires non stéroïdiens/pharmacologie , Produits de contraste/effets indésirables , Éthanolamines/pharmacologie , Acides palmitiques/pharmacologie , Insuffisance rénale/anatomopathologie , Protéine de la phase aigüe , Amides , Animaux , Azote uréique sanguin , Produits de contraste/administration et posologie , Créatinine/sang , Diabète expérimental , Modèles animaux de maladie humaine , Glutathione transferase/urine , Méthode TUNEL , Iohexol/administration et posologie , Iohexol/effets indésirables , Iopamidol/administration et posologie , Iopamidol/effets indésirables , Iopamidol/analogues et dérivés , Rein/effets des médicaments et des substances chimiques , Rein/anatomopathologie , Rein/chirurgie , Lipocaline-2 , Lipocalines/sang , Mâle , Taille de particule , Potassium/sang , Protéines proto-oncogènes/sang , Rats , Rat Wistar , Insuffisance rénale/induit chimiquement , Insuffisance rénale/traitement médicamenteux , Sodium/sang , Streptozocine/administration et posologie , Streptozocine/effets indésirables
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE